



EmphyCorp N115 Rx Nasal and Oral Spray Drug Pipeline w/ No Side Effects 12/2/2025

8 Drug Patents (3 New: Hypoxemia & Dyspnea & Coughing, Apoptosis of Myofibroblasts, Coronavirus/Flu) (x = completed)

| Treatment | Drug | Phase 1 | Phase 2 | Phase 3 | NDA | Medical Endpoints Achieved |
|--|---------------------------------------|---|----------------------|--|--------------------------------|---|
| Idiopathic Pulmonary Fibrosis (Orphan Drug Designation for all ILD) No Adverse Events Reported | N115 Non-Steroidal Nasal Spray | X | X | X - Pivotal Phase III Trial for NDA | X FDA Approval Ready | 73% Reduction in Coughing & Improved Lung Function (Hypoxemia, Dyspnea) |
| Pulmonary Fibrosis & IPF (Orphan Drug Designation for all ILD) No Adverse Events Reported | N115 Non-Steroidal Nasal Spray | X | X Orphan Drug NDA | Protocol ready | | Met (8) Medical Endpoints. Clinically & Statistically Significant Results |
| Cystic Fibrosis (Orphan Drug Designation for all ILD) | N115 Non-Steroidal Nasal Spray | X | X | | | FEV1, Coughing, Hypoxemia, Dyspnea, and Sleeping Better |
| Moderate & Severe COPD Treatment No Adverse Events Reported (Can replace Sprays with Steroids and PED3/PED4 Inhibitors) | N115 Non-Steroidal Nasal Spray | X | X | Protocol Ready | | Phase 3 in 2026 FEV1, Coughing, Hypoxemia, Dyspnea, Bronchodilator (Safe for Diabetic, Hypertensives and Pregnant Women) |
| Long COVID Treatment (No Adverse Events Reported in a Small Clinical Trial) | N115 Non-Steroidal Nasal Spray | X | X | X Protocol Ready | | Expanded Phase 3 in 2026. Met (8) Medical Endpoints (10 Million US Patients) |
| Allergic Rhinitis No Adverse Events Reported (Can replace Nasal Sprays with Steroids, Oxymetazoline, and Phenylephrine) | N115 Non-Steroidal Nasal Spray | X | X | Protocol Ready | | Immediate Relief of Congestion, Allergy Symptoms (Safe use for 30 to 60 million US Diabetic, Hypertensives, and Pregnant Women) |
| Influenza Treatment & Preventative (No Adverse Effects) | N115 Non-Steroidal Nasal Spray | X | X | Protocol Ready | | Increases Nasal Nitric Oxide to kill Viruses/Shut IL-6 |
| COVID-19 Treatment (No Adverse Effects in a Small Clinical Trial) | N115 Non-Steroidal Nasal Spray | X | X | | | Increases Nasal Nitric Oxide to kill Viruses/Shut IL-6 |
| High Blood Pressure and Pulmonary Hypertension Treatment | N115 Non-Steroidal Nasal & Oral Spray | Pilot Study Plan | | | | Discovered in Phase II Severe COPD Patient Clinicals |
| Alzheimer's | N115 Nasal Spray | X | Pilot Study | | | Helps relieve symptoms |
| Concussions | N115 Nasal Spray | X | Pilot Study | | | Helps relieve symptoms |
| Parkinson's | N115 Nasal Spray | X | Pilot Study | | | Helps relieve symptoms |
| Cancer Pre-Treatment | N115 Nasal Spray | X | Pilot Study | | | Protects Healthy Cells |
| Racehorses - Increase SaO2 | N115 Nasal Spray | Pilot Study | | | | Stops Nasal Bleeding |
| Patented OTC Nasal Spray sold US/China | N115 Nasal Spray | (1) US and (3) Chinese Approved Nasal Sprays | | | | 3 Million Patients Treated |
| To Date: (28) Sets of Human Clinical Trials completed. (6) Peer Reviews & 38 NIH studies | N115 Nasal Spray and Oral Spray | (3) New Drug Patents for the Treatment of all Lung and Sinus Diseases & Slowing/Stopping Lung Fibrosis | | | | (8) Drug Patents – (3) New Composition Patents for all lung and sinus diseases |